Assessments for Prodromal Alzheimer’s Disease Having Positive Amyloid Pathology Using Plasma Biomarkers And APOE Genotype
Pei‐Ning Wang, Ming‐Jang Chiu, Marwan N Sabbagh, Charles SY Yang · 2025
Read Assessments for Prodromal Alzheimer’s Disease Having Positive Amyloid Pathology Using Plasma Biomarkers And APOE Genotype by Pei‐Ning Wang, Ming‐Jang Chiu, Marwan N Sabbagh, Charles SY Yang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715267.txt.
Description
Pei-Ning Wang and three co-authors built a blood-based way to find early Alzheimer's disease patients for drug care. New drugs can slow the disease at its first stage, when thought slips just a bit. But proof of amyloid in the brain is a must before care starts, and brain scans are scarce and dear. A cheap blood screen could sort who should get a scan.
The team ran a multi-site study of people with mild memory loss or early dementia. Two blood scores, each built from amyloid and tau levels, sorted the early stage with more than eighty-five percent accuracy. A blood amyloid score plus a known gene type then foretold a clear brain scan in more than eighty-four percent of cases. The flow could ease the jam in clinics and widen the reach of the new drugs.
Catalog record
| CREATOR | Pei‐Ning Wang, Ming‐Jang Chiu, Marwan N Sabbagh, Charles SY Yang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |